| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
INVITED REVIEW
Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, Florida
Submitted 14 December 2006 ; accepted in final form 16 March 2007
In many forms of experimental kidney diseases, renal VEGF is low, and administering VEGF can be shown to be protective. A paradox occurs in diabetes, in which renal VEGF levels are high and a deleterious effect of VEGF on kidney disease has been shown. We have hypothesized that endothelial dysfunction induced by hyperglycemia or other factors may underlie the pathogenic mechanisms of a high VEGF state. VEGF normally stimulates endothelial nitric oxide (NO) release and acts in concert with elevated NO levels as a trophic factor for vascular endothelium. The increased NO derived from the endothelial cell acts as an inhibitory factor that prevents excess endothelial cell proliferation, vascular smooth muscle cell proliferation, and macrophage infiltration. In the setting where NO bioavailability is reduced in diabetes, high levels of VEGF lead to excessive endothelial cell proliferation, stimulation of macrophage chemotaxis, and vascular smooth muscle cell activation. Consistent with this hypothesis is our recent observation that diabetes induced in endothelial NO-deficient mice results in clinical and histological features identical to human diabetic nephropathy. The discovery of the key role for impaired endothelial NO bioavailability in the stimulation of VEGF and VEGF-dependent disease may provide key insights into not only the pathogenesis of diabetic nephropathy but also the utility and hazard of administering VEGF as a treatment for kidney disease.
NO; angiogenesis
This article has been cited by other articles:
|
|
 |
|
  S. C.W. Tang, L. Y.Y. Chan, J. C.K. Leung, A. S. Cheng, K. W. Chan, H. Y. Lan, and K. N. Lai Bradykinin and high glucose promote renal tubular inflammation Nephrol. Dial. Transplant., November 18, 2009; (2009) gfp599v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long Abnormal Angiogenesis in Diabetic Nephropathy Diabetes, July 1, 2009; 58(7): 1471 - 1478. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mu, D. A. Long, X. Ouyang, A. Agarwal, P. E. Cruz, C. A. Roncal, T. Nakagawa, X. Yu, W. W. Hauswirth, and R. J. Johnson Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism Am J Physiol Renal Physiol, January 1, 2009; 296(1): F145 - F152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Acevedo, I. Londono, M. Oubaha, L. Ghitescu, and M. Bendayan Glomerular CD34 Expression in Short- and Long-term Diabetes J. Histochem. Cytochem., June 1, 2008; 56(6): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius III From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy Diabetes, June 1, 2008; 57(6): 1439 - 1445. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Basile, K. Fredrich, B. Chelladurai, E. C. Leonard, and A. R. Parrish Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor Am J Physiol Renal Physiol, April 1, 2008; 294(4): F928 - F936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Navarro-Gonzalez and C. Mora-Fernandez The Role of Inflammatory Cytokines in Diabetic Nephropathy J. Am. Soc. Nephrol., March 1, 2008; 19(3): 433 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa, M. Segal, B. Croker, and R. J. Johnson A breakthrough in diabetic nephropathy: the role of endothelial dysfunction Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2775 - 2777. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
